Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

I never said that DES is in p3 trial. I said if it has a good/stellar data this coming January, it can be a factor in their decision to acquire auph since the only factors they can rely on right now are the p-values, the stellar p2 results of Voclosporin LN trial and the derisk attribute to this company. Now, if there are multiple possible acquirers eyeing this company, they will have to make a decision based on these factors if they don’t want wait for the p3 results.

And thank you for keeping this board awake.